叶状天疱疮的临床人口学特征:对103例非地方性天疱疮患者的临床资料进行回顾性分析。

IF 2.8 4区 医学 Q1 DERMATOLOGY
Dipankar De, Apoorva Sharma, Vinod Hanumanthu, Debajyoti Chatterjee, Uma Nahar Saikia, Biman Saikia, Rahul Mahajan, Sanjeev Handa
{"title":"叶状天疱疮的临床人口学特征:对103例非地方性天疱疮患者的临床资料进行回顾性分析。","authors":"Dipankar De, Apoorva Sharma, Vinod Hanumanthu, Debajyoti Chatterjee, Uma Nahar Saikia, Biman Saikia, Rahul Mahajan, Sanjeev Handa","doi":"10.1093/ced/llaf408","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pemphigus foliaceus (PF) is an uncommon autoimmune blistering disease characterized by superficial blistering and erosions of the skin. Literature on PF globally is limited. Understanding the clinicodemographic heterogeneity in PF is crucial for offering improved outcomes for affected individuals.</p><p><strong>Objective: </strong>To study the clinico-demographic characteristics and treatment outcomes of PF patients in north India.</p><p><strong>Methods: </strong>A retrospective study of patients with PF registered to our clinic between November 2013 and June 2023 at a tertiary care centre in north India was conducted.</p><p><strong>Results: </strong>A total of 103 patients with PF were included in the study. The mean age at disease onset was 40.4± 15.7 years, with a male-to-female ratio of 1.7:1. The median duration of the disease at presentation was 18 months (ranging from 1 to 240 months). The most commonly prescribed treatment was topical corticosteroids (n=98, 95.1%) or oral corticosteroids (n=97, 94.1%), either alone or in combination with steroid-sparing adjuvants. Rituximab was the commonest adjuvant used in 45 patients (43.6%). Overall, 78 (75.7%) patients achieved clinical remission on minimal therapy (CRmin) in 6.5 ± 3.9 months and clinical remission off therapy (CRoff) was achieved in 10.4 ± 6.0 months in 69 (66.9%) patients. Among patients in the rituximab group, CRmin was achieved in 41 patients (91.1%) in 6.3 ± 4.6 months and CRoff was achieved in 37 cases (82.2%) in 9 ± 5.6 months.</p><p><strong>Limitations: </strong>The study design is retrospective. Anti-desmoglein antibody titres in the serum were not routinely assessed.</p><p><strong>Conclusion: </strong>PF in the present study was more common in middle-aged males. Corticosteroids (topical/systemic) formed the mainstay of therapy, with rituximab being the most commonly used steroid-sparing adjuvant. Prospective studies in a larger cohort are required in the future for better understanding of this disease in non-endemic locations.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinico-demographic characteristics of pemphigus foliaceus: Retrospective analysis of clinic-based data of 103 patients in a non-endemic location.\",\"authors\":\"Dipankar De, Apoorva Sharma, Vinod Hanumanthu, Debajyoti Chatterjee, Uma Nahar Saikia, Biman Saikia, Rahul Mahajan, Sanjeev Handa\",\"doi\":\"10.1093/ced/llaf408\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Pemphigus foliaceus (PF) is an uncommon autoimmune blistering disease characterized by superficial blistering and erosions of the skin. Literature on PF globally is limited. Understanding the clinicodemographic heterogeneity in PF is crucial for offering improved outcomes for affected individuals.</p><p><strong>Objective: </strong>To study the clinico-demographic characteristics and treatment outcomes of PF patients in north India.</p><p><strong>Methods: </strong>A retrospective study of patients with PF registered to our clinic between November 2013 and June 2023 at a tertiary care centre in north India was conducted.</p><p><strong>Results: </strong>A total of 103 patients with PF were included in the study. The mean age at disease onset was 40.4± 15.7 years, with a male-to-female ratio of 1.7:1. The median duration of the disease at presentation was 18 months (ranging from 1 to 240 months). The most commonly prescribed treatment was topical corticosteroids (n=98, 95.1%) or oral corticosteroids (n=97, 94.1%), either alone or in combination with steroid-sparing adjuvants. Rituximab was the commonest adjuvant used in 45 patients (43.6%). Overall, 78 (75.7%) patients achieved clinical remission on minimal therapy (CRmin) in 6.5 ± 3.9 months and clinical remission off therapy (CRoff) was achieved in 10.4 ± 6.0 months in 69 (66.9%) patients. Among patients in the rituximab group, CRmin was achieved in 41 patients (91.1%) in 6.3 ± 4.6 months and CRoff was achieved in 37 cases (82.2%) in 9 ± 5.6 months.</p><p><strong>Limitations: </strong>The study design is retrospective. Anti-desmoglein antibody titres in the serum were not routinely assessed.</p><p><strong>Conclusion: </strong>PF in the present study was more common in middle-aged males. Corticosteroids (topical/systemic) formed the mainstay of therapy, with rituximab being the most commonly used steroid-sparing adjuvant. Prospective studies in a larger cohort are required in the future for better understanding of this disease in non-endemic locations.</p>\",\"PeriodicalId\":10324,\"journal\":{\"name\":\"Clinical and Experimental Dermatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ced/llaf408\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ced/llaf408","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:叶状天疱疮(PF)是一种罕见的自身免疫性起泡疾病,其特征是皮肤表面起泡和糜烂。全球范围内关于PF的文献是有限的。了解PF的临床人口学异质性对于改善患者的预后至关重要。目的:研究印度北部地区PF患者的临床人口学特征及治疗效果。方法:对2013年11月至2023年6月在印度北部三级保健中心登记的PF患者进行回顾性研究。结果:共纳入103例PF患者。平均发病年龄40.4±15.7岁,男女比例为1.7:1。疾病出现时的中位病程为18个月(范围从1到240个月)。最常用的处方治疗方法是外用皮质类固醇(n=98, 95.1%)或口服皮质类固醇(n=97, 94.1%),可以单独使用,也可以联合使用节省类固醇的佐剂。45例患者(43.6%)使用利妥昔单抗是最常见的辅助药物。总体而言,78例(75.7%)患者在6.5±3.9个月达到最低限度治疗(CRmin)的临床缓解,69例(66.9%)患者在10.4±6.0个月达到临床缓解(CRoff)。利妥昔单抗组患者中,41例(91.1%)患者在6.3±4.6个月达到CRmin, 37例(82.2%)患者在9±5.6个月达到CRoff。局限性:研究设计是回顾性的。血清中抗粘连蛋白抗体滴度未常规评估。结论:本研究中PF多见于中年男性。皮质类固醇(局部/全身)是主要的治疗方法,而利妥昔单抗是最常用的不使用类固醇的辅助药物。未来需要在更大的队列中进行前瞻性研究,以便更好地了解非流行地区的这种疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinico-demographic characteristics of pemphigus foliaceus: Retrospective analysis of clinic-based data of 103 patients in a non-endemic location.

Background: Pemphigus foliaceus (PF) is an uncommon autoimmune blistering disease characterized by superficial blistering and erosions of the skin. Literature on PF globally is limited. Understanding the clinicodemographic heterogeneity in PF is crucial for offering improved outcomes for affected individuals.

Objective: To study the clinico-demographic characteristics and treatment outcomes of PF patients in north India.

Methods: A retrospective study of patients with PF registered to our clinic between November 2013 and June 2023 at a tertiary care centre in north India was conducted.

Results: A total of 103 patients with PF were included in the study. The mean age at disease onset was 40.4± 15.7 years, with a male-to-female ratio of 1.7:1. The median duration of the disease at presentation was 18 months (ranging from 1 to 240 months). The most commonly prescribed treatment was topical corticosteroids (n=98, 95.1%) or oral corticosteroids (n=97, 94.1%), either alone or in combination with steroid-sparing adjuvants. Rituximab was the commonest adjuvant used in 45 patients (43.6%). Overall, 78 (75.7%) patients achieved clinical remission on minimal therapy (CRmin) in 6.5 ± 3.9 months and clinical remission off therapy (CRoff) was achieved in 10.4 ± 6.0 months in 69 (66.9%) patients. Among patients in the rituximab group, CRmin was achieved in 41 patients (91.1%) in 6.3 ± 4.6 months and CRoff was achieved in 37 cases (82.2%) in 9 ± 5.6 months.

Limitations: The study design is retrospective. Anti-desmoglein antibody titres in the serum were not routinely assessed.

Conclusion: PF in the present study was more common in middle-aged males. Corticosteroids (topical/systemic) formed the mainstay of therapy, with rituximab being the most commonly used steroid-sparing adjuvant. Prospective studies in a larger cohort are required in the future for better understanding of this disease in non-endemic locations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.20
自引率
2.40%
发文量
389
审稿时长
3-8 weeks
期刊介绍: Clinical and Experimental Dermatology (CED) is a unique provider of relevant and educational material for practising clinicians and dermatological researchers. We support continuing professional development (CPD) of dermatology specialists to advance the understanding, management and treatment of skin disease in order to improve patient outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信